Integral Health Asset Management LLC Acquires 50,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Integral Health Asset Management LLC lifted its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 25.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,000 shares of the company's stock after acquiring an additional 50,000 shares during the period. Integral Health Asset Management LLC owned 0.33% of Nurix Therapeutics worth $4,710,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in NRIX. US Bancorp DE lifted its position in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after buying an additional 842 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in Nurix Therapeutics during the fourth quarter valued at approximately $87,000. Summit Investment Advisors Inc. raised its position in Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after purchasing an additional 877 shares during the period. BNP Paribas Financial Markets purchased a new stake in Nurix Therapeutics during the fourth quarter valued at approximately $164,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Nurix Therapeutics during the fourth quarter valued at approximately $207,000.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider now directly owns 61,516 shares of the company's stock, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at $488,660.76. The trade was a 14.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,838 shares of company stock valued at $221,500 in the last ninety days. Corporate insiders own 7.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on NRIX shares. Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Royal Bank of Canada increased their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. JPMorgan Chase & Co. dropped their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Finally, Morgan Stanley increased their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research report on Monday, February 3rd. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.44.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $9.50 on Monday. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56. The company has a market capitalization of $724.24 million, a price-to-earnings ratio of -3.29 and a beta of 2.23. The firm has a 50-day simple moving average of $11.49 and a 200-day simple moving average of $17.35.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same quarter last year, the firm earned ($0.76) earnings per share. Equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.